Posted by Michael Wonder on 08 Nov 2021
The hurried push by Congress to address drug costs shouldn’t undermine the vast savings from generics and biosimilars
6 November 2021 - Americans rightfully expect Congress to address the ever increasing prices of brand-name prescription drugs.
But the wholesale policy changes now under rushed consideration in Congress will undermine the only proven solution to this long-standing problem: competition from FDA approved generic and biosimilar medicines.
